Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc (NASDAQ: POAI) delivers AI-powered solutions for personalized cancer treatment through its integrated biobank data and machine learning platforms. This news hub provides investors and researchers with essential updates about the company's advancements in precision oncology.
Access real-time information on POAI's FDA-cleared medical systems, clinical trial partnerships, and AI-driven drug discovery milestones. Our curated collection includes earnings reports, technology validations, and strategic collaborations that demonstrate the company's progress in transforming cancer care.
Key updates cover three operational segments: AI-driven tumor modeling from Pittsburgh labs, biopharma contract research developments in Birmingham, and STREAMWAY System adoption in clinical settings. Stay informed about biomarker discovery breakthroughs and peer-reviewed study publications.
Bookmark this page for streamlined access to POAI's verified financial disclosures, scientific presentations, and regulatory filings. Check regularly for updates on how the company's 150,000+ tumor sample database informs next-generation oncology solutions.
Predictive Oncology (NASDAQ: POAI) has developed a novel approach to repurpose abandoned oncology drugs using active machine learning and their biobank of patient-derived tumor cells. The company successfully identified three promising compounds in less than 12 weeks:
1. Afuresertib (Akt inhibitor): Showed strong results in ovarian and colon tumors
2. Alisertib (Aurora A Inhibitor): Outperformed standard care drugs in colon and breast cancer
3. Entinostat (HDAC1/3 inhibitor): Demonstrated strong response in colon samples
The screening method efficiently evaluated these compounds against tumor indications that were previously unexplored. Notably, Alisertib and Entinostat outperformed Oxaliplatin in colon tumor treatment, while Alisertib also showed superior results compared to Ribociclib in breast cancer treatment.
Predictive Oncology (POAI) reported its financial results for Q4 and full-year 2024, posting a $10.8 million loss from continuing operations on revenue of $1.6 million. The company is progressing toward a definitive merger agreement with Renovaro Inc, having received the first tranche of financing to integrate AI/ML platforms and expand operations.
Key developments include the sale of Skyline Medical subsidiary to DeRoyal Industries, partnership with Tecan Group for high-throughput drug screening, and planned European launch of ChemoFx® drug response assay. The company raised over $3.0 million in Q1 2025 through various financing activities.
Financial highlights: Cash position decreased to $734,673 from $8.7 million year-over-year, with stockholder's deficit of $(202,610). Revenue remained relatively flat at $1.62 million compared to $1.63 million in 2023. Operating expenses decreased across all categories, with general and administrative expenses down by $961,025 to $7.42 million.
Predictive Oncology (NASDAQ: POAI) has successfully developed predictive models from 21 unique compounds sourced from the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute. The company's AI-driven platform evaluated these compounds for tumor response across breast, colon, and ovary cancer types.
Key findings include:
- Three compounds showed stronger tumor response than the benchmark drug Doxorubicin across all tested tumor types
- A fourth compound demonstrated strong response in ovary and colon models
- Three additional compounds showed significant 'hit responses' across all tumor types
- The ML model achieved 73% prediction coverage while only requiring 7% of possible wet lab experiments, potentially saving up to two years of laboratory testing
The NPDC library, one of the largest pharmaceutically viable natural products collections in the United States, contains specimens from global biodiverse hotspots. Natural products have historically contributed to at least half of approved small-molecule drugs in the past three decades.
Predictive Oncology (NASDAQ: POAI) has completed the sale of its Skyline Medical subsidiary's assets to DeRoyal Industries, a global medical products manufacturer. The transaction involves the STREAMWAY® System, an FDA-cleared direct-to-drain wall suction waste fluid management technology.
The sale aligns with POAI's strategic focus on AI-driven drug discovery and comes ahead of its planned merger with Renovaro Biosciences. The company had implemented a restructuring plan for Skyline Medical in late 2023, successfully returning the unit to profitability by the end of 2024.
DeRoyal Industries will integrate the STREAMWAY® System into its product portfolio under its own brand, maintaining service continuity for existing customers while expanding market reach. The system provides healthcare professionals with an automated solution for managing potentially hazardous fluids during medical procedures, designed to reduce manual handling and eliminate spillage risks.
Predictive Oncology (NASDAQ: POAI) has received the first tranche of financing from Renovaro Biosciences (NASDAQ: RENB) to begin integrating AI/ML platforms, laboratory capabilities, and business development efforts across Europe and the US. The companies are moving towards finalizing a definitive merger agreement, expected within weeks.
The merger aims to combine Predictive's AI-driven drug discovery platform, which includes a biobank of over 150,000 patient tumor samples and 200,000 pathology slides, with Renovaro's multi-disciplinary AI and multi-omic expertise. This integration has been enhanced by Renovaro's recent acquisition of BioSymetrics, which expands opportunities in biomarker and drug discovery, along with diagnostic applications in oncology.
The combined entity will focus on improving cancer patient outcomes through earlier diagnosis, biomarker discovery, and targeted therapies. The merger is expected to enhance shareholder value and strengthen the company's position in capital markets.
Predictive Oncology (NASDAQ: POAI) has successfully closed its previously announced registered direct offering, selling 363,336 shares of common stock at $1.50 per share, priced at-the-market under Nasdaq rules. The offering generated gross proceeds of approximately $545,004 before deducting placement agent fees and other expenses. H.C. Wainwright & Co. served as the exclusive placement agent.
The company plans to utilize the net proceeds for working capital and general corporate purposes. The offering was conducted under a shelf registration statement on Form S-3 that became effective on May 21, 2024. A final prospectus supplement and accompanying prospectus were filed with the SEC on February 19, 2025.
Predictive Oncology (NASDAQ: POAI), an AI-driven drug discovery and biologics company, has announced a registered direct offering of 363,336 shares of common stock priced at $1.50 per share. The offering, priced at-the-market under Nasdaq rules, is expected to generate gross proceeds of $545,004 before deducting fees and expenses.
The offering is expected to close on February 19, 2025, with H.C. Wainwright & Co. serving as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made pursuant to an effective S-3 shelf registration statement previously filed with the SEC.
Predictive Oncology (NASDAQ: POAI) reported successful results in its drug repurposing initiative using artificial intelligence. The company identified several abandoned or discontinued pharmaceutical drugs for potential repurposing in cancer treatment, particularly for ovarian, colon, and breast cancer.
Using its proprietary AI and machine learning platform, combined with its biobank of primary tumor samples and drug response data, POAI's system made 964 confident predictions from just 92 laboratory experiments, covering 79% of all possible experiments. This eliminated approximately 18 months of wet lab testing and identified two drugs that outperformed a standard colon cancer treatment.
The company evaluated six specific drug candidates, including inhibitors targeting Akt, Aurora A, PI3Kα, HDAC1/3, VEGFR2/KDR, and PARP1/2. The drug repurposing market is projected to grow from $32.1 billion in 2023 to $51.8 billion by 2033, representing a 4.5% CAGR.
Predictive Oncology (NASDAQ: POAI) announced positive results from a collaborative study with Tecan, at the 2025 SLAS International Conference. The study focused on utilizing patient-derived tumor spheroids (PDTS) from POAI's biobank of cryopreserved tumor specimens for drug screening.
The research demonstrated successful transition from 2D cell culture to cryopreservation and then to 3D cell culture, using breast, colon, and ovary samples with known drug response data. The collaboration leverages Tecan's SparkCyto instrument and 3DAI software for automated analysis of tumor spheroids.
This advancement addresses a key challenge in cancer research: the accessibility and scalability of primary tumor cells. The high-throughput screening market is projected to reach $69.5 billion by 2032, with a CAGR of 12.18%, according to SNS Insider research.
AIRNA has appointed Matthew Hawryluk, Ph.D., MBA as Chief Business Officer. Dr. Hawryluk joins from Gritstone bio, where he served as Executive Vice President and Chief Business Officer. He brings extensive experience in strategic partnerships and business development, having held senior roles at Foundation Medicine and Thermo Fisher Scientific. He currently serves on the Board of Directors at Predictive Oncology (NASDAQ: POAI) and Pear Bio.
The appointment comes at a important time as AIRNA prepares to advance its first RNA editing therapeutic to clinical trials, focusing on alpha-1 antitrypsin deficiency. The company also announced the appointment of Colleen Tucker as Head of People, bringing experience from Akouos, Entasis Therapeutics, and Momenta Pharmaceuticals.
